EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.
|Number of pages||9|
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 2008|